Nav: Home

A scientific advance in studying early-stage lung cancer

September 15, 2020

Lung cancer is the leading cancer killer in the U.S. It is often missed in its earlier stages, and while recent imaging advances have enabled earlier detection, there are still no targeted treatments for early-stage lung cancers. New research from Boston Children's Hospital, in collaboration with Boston University and UCLA, provides an accelerated platform for identifying and testing potential treatments: "organoids" created from lung cells.

As reported September 4 in Cell Stem Cell, the organoids enabled the researchers to track one common, hard-to-treat lung tumor -- adenocarcinoma driven by mutation in the KRAS gene -- from its origins, capturing the molecular changes that took place as it progressed.

The research team, led by Carla Kim, PhD, of Boston Children's Stem Cell Program, used four parallel models of early lung cancer: tumor samples from patients with early (stage 1A) lung cancer, genetically engineered mouse models, and lung organoids derived from either mouse lung stem cells or from lung cells created from human induced pluripotent stem cells.

"We know very little about the early events that transform a normal lung epithelial cell into a cancer cell," says Kim, co-senior author on the paper with Jane Yanagawa, MD, of UCLA and Darrell Kotton, MD, of the Boston University School of Medicine. "In this study, we were able to use early-stage samples from lung cancer patients to show that our organoids truly mimic what happens in patients at the very early stages. We can see changes in the organoids within seven days that can take months to see in mice and even longer, probably years, in patients."

Tracking an unfolding lung cancer

The researchers introduced the cancer-initiating KRAS mutation into the lung organoids' alveolar progenitor cells. They then used single-cell RNA sequencing to see what genes turned on, or expressed, as a result. These studies revealed reduced expression of genes that are markers of mature lung alveolar cells, and increased expression of genes involved in early lung development -- known markers of cancer progression. Studies in mice and in the patient tumor samples mirrored findings in the organoids.

"KRAS-mutant tumors are usually already resistant to therapy by the time they are diagnosed," notes Kim. "These studies lay a groundwork for finding new therapeutic avenues in the future when an early-stage lung cancer is detected."

Although this study looked at KRAS-driven lung cancer, the researchers believe that the organoid approach could facilitate the study of other kinds of cancer, including testing of candidate drugs.

"The collaborating teams really made progress together in understanding a stage of lung cancer that has been very tough to study in humans," says Kotton. "We hope these new human and lung organoid models of early lung cancer formation will now serve as powerful drug development platforms."
-end-
Antonella Dost and Aaron Moye, PhD, of the Boston Children's Stem Cell Program were co-first authors on the paper. Supporters of the study include Boehringer Ingelheim Fonds, the National Institutes of Health (R01 HL090136, R01 HL132266, R01 HL125821, U01 HL100402 RFA-HL-09-004, R35HL150876-01, R24HL123828, U01TR001810, R01HL128172, R01HL095993, R01HL122442, U01HL134745, and U01HL134766), the Damon Runyon Cancer Research Foundation (DRG:2368-19), the Burroughs Wellcome Fund, Hope Funds for Cancer Research, an IASLC Young Investigator Fellowship, the American Cancer Society (RSG-08-082-01-MGO), the V Foundation for Cancer Research, the Thoracic Foundation, the Ellison Foundation, the American Lung Association (LCD-619492), the Harvard Stem Cell Institute, and the Lung Cancer Initiative at Johnson & Johnson.

About Boston Children's Hospital

Boston Children's Hospital is ranked the #1 children's hospital in the nation by U.S. News & World Report and is the primary pediatric teaching affiliate of Harvard Medical School. Home to the world's largest research enterprise based at a pediatric medical center, its discoveries have benefited both children and adults since 1869. Today, 3,000 researchers and scientific staff, including 9 members of the National Academy of Sciences, 21 members of the National Academy of Medicine and 12 Howard Hughes Medical Investigators comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's is now a 415-bed comprehensive center for pediatric and adolescent health care. For more, visit our Discoveries blog and follow us on social media @BostonChildrens, @BCH_Innovation, Facebook and YouTube.

Boston Children's Hospital

Related Lung Cancer Articles:

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.
Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Debbie Millman: Designing Our Lives
From prehistoric cave art to today's social media feeds, to design is to be human. This hour, designer Debbie Millman guides us through a world made and remade–and helps us design our own paths.
Now Playing: Science for the People

#574 State of the Heart
This week we focus on heart disease, heart failure, what blood pressure is and why it's bad when it's high. Host Rachelle Saunders talks with physician, clinical researcher, and writer Haider Warraich about his book "State of the Heart: Exploring the History, Science, and Future of Cardiac Disease" and the ails of our hearts.
Now Playing: Radiolab

Insomnia Line
Coronasomnia is a not-so-surprising side-effect of the global pandemic. More and more of us are having trouble falling asleep. We wanted to find a way to get inside that nighttime world, to see why people are awake and what they are thinking about. So what'd Radiolab decide to do?  Open up the phone lines and talk to you. We created an insomnia hotline and on this week's experimental episode, we stayed up all night, taking hundreds of calls, spilling secrets, and at long last, watching the sunrise peek through.   This episode was produced by Lulu Miller with Rachael Cusick, Tracie Hunte, Tobin Low, Sarah Qari, Molly Webster, Pat Walters, Shima Oliaee, and Jonny Moens. Want more Radiolab in your life? Sign up for our newsletter! We share our latest favorites: articles, tv shows, funny Youtube videos, chocolate chip cookie recipes, and more. Support Radiolab by becoming a member today at Radiolab.org/donate.